<DOC>
	<DOCNO>NCT01209078</DOCNO>
	<brief_summary>This study determine safety , tolerability efficacy GSK1322322 verse Linezolid subject Acute Bacterial Skin Skin Structure Infection ( ABSSSI ) .</brief_summary>
	<brief_title>GSK1322322 Versus Linezolid Treatment Acute Bacterial Skin Skin Structure Infection</brief_title>
	<detailed_description>This phase IIa , multicenter , randomize , parallel group , double-blind , double dummy study ass safety , tolerability , efficacy GSK1322322 give 1500mg twice daily 10-day period versus linezolid ( 600mg twice daily 10 day ) adult suspect Gram positive Acute Bacterial Skin Skin Structure Infection currently receive antibacterial therapy . Subjects randomize ( 2:1 ) GSK1322322 linezolid . This study consist screen visit , 10-day treatment period , follow-up evaluation 7 28 day follow last dose .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Skin Diseases , Infectious</mesh_term>
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Linezolid</mesh_term>
	<criteria>Male female subject age 18 year old time signing inform consent Male subject must agree use one contraception method list A female eligible enter participate study nonchildbearing potential The subject diagnosis ABSSSI define one following : wound infection cellulitis develop within 30 day surgery trauma ; abscess cellulitis , cellulitis develop 7 day enrollment worsen past 48 hour OR investigator 's opinion patient 's condition warrant systemic oral antibiotic therapy The subject least 2 additional sign symptom skin infection : purulence , erythema without induration , fluctuation , heat/localized warmth , pain/tenderness The subject least 1 systemic marker infection : Lymphadenopathy , Fever ( &gt; 38 degree Celsius ) , White Blood Cell elevation , Creatinine Reactive Protein ( CRP ) &gt; Upper Limit Normal ( ULN ) The subject give write , inform , dated consent participate study QTcB QTcF &lt; 450 msec ; QTc &lt; 480 msec subject Bundle Branch Block Aspartate aminotransferase ( AST ) Alanine aminotransferase ( ALT ) &lt; 2xULN ; bilirubin &lt; 1.0xULN Current chronic history liver disease , know hepatic biliary abnormality The subject diagnose Acquired immune deficiency syndrome ( AIDS ) Body mass index ( BMI ) &gt; 40 kg/m2 The subject demonstrate previous hypersensitivity reaction GSK1322322 , oxazolidinones The subject secondarily infect animal/human bite The subject chronic ulcerative lesion likely polymicrobial cause anaerobic organism unlikely Staphylococcus aureus Streptococcus pyogenes causative agent The subject underlie skin disease , preexist eczematous dermatitis , clinical evidence secondary infection The subject infection would normally high cure rate surgical incision alone The subject bacterial skin infection , due extent , depth severity clinical presentation , opinion investigator , appropriately treated oral antibiotic The subject receive one dose treatment systemic and/or topical antibacterial within 7 day The subject currently receive vasopressor The subject currently receive adrenergic agent The subject currently receive serotonergic reuptake inhibitor The subject currently receive monoamine oxidase inhibitors The subject document clinical history pseudomembranous colitis The subject know , preexist myelosuppression , history myelosuppression prior linezolid use , currently receive medication produce bone marrow suppression The subject history seizures The subject history severe renal failure undergo dialysis The subject serious underlying disease could imminently lifethreatening The subject previously enrol study The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product Subject unable discontinue use prescription drug list protocol nonprescription drug , include vitamin , herbal dietary supplement prior first dose study medication first follow visit Lactating female pregnant female determine positive urine pregnancy test screen prior dose</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>methicillin-resistant Staphylococcus aureus</keyword>
	<keyword>linezolid</keyword>
	<keyword>repeat dose</keyword>
	<keyword>GSK1322322</keyword>
</DOC>